Archive


Category: ~500M

  • AstraZeneca to Acquire Caelum for ~500M

    Shots: Alexion has exercised its option to acquire all remaining equity in Caelum for CAEL-101 which is currently being evaluated in P-III CARES clinical program that consists of 2 P-III trials in combination with SoC therapy for AL amyloidosis Caelum to receive ~$150M as an option exercise fee in addition to ~$350M upon the achievement […]